Zhejiang Huahai Pharmaceutical (600521.SH) has obtained drug registration certificates for multiple drugs.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company recently received the "Drug Registration Certificate" for the injection of Cytarabine, Agomelatine tablets, and Carbidopa Levodopa sustained-release tablets issued and approved by the National Medical Products Administration (referred to as the "NMPA"). It is reported that Cytarabine injections are used for induction and maintenance therapy of acute non-lymphocytic leukemia in adults and children. This product also has therapeutic effects on other types of leukemia, such as acute lymphocytic leukemia and chronic myelogenous leukemia (blast phase). Agomelatine tablets are used to treat depression in adults. Carbidopa Levodopa sustained-release tablets are used to treat primary Parkinson's disease; post-encephalitic Parkinson's syndrome; symptomatic Parkinson's syndrome (carbon monoxide or manganese poisoning); in patients who have previously used a combination of levodopa/decarboxylase inhibitors or levodopa monotherapy and have experienced worsening of symptoms, such as peak-dose motor fluctuations, motor complications, or similar short-term motor fluctuations, it can reduce the "off" time (the state where motor symptoms (e.g., rigidity, bradykinesia) and non-motor symptoms (e.g., pain, anxiety) suddenly worsen due to a decrease in dopamine concentration or diminishing efficacy during drug therapy).